Under the Pa	iperwork	Reduction Act of 199:	5. Do nemon) Second to record for the second for	U.S. Petent and	Approved i	PTC/SB/21 (09-04 for use through 07/31/2006, OMB 0651-0031 Diffice; U.S. DEPARTMENT OF COMMERCE
				i are required to respond to a collection of information unless it displays a valid OMB control numb Application Number 10/088,250			
TRANSMITTAL			Filing Date				
FORM			First Named Inventor	David	David M. FINK, et al		
			Art Unit	1626	1626		
(to be used for all correspondence after initial filing)			Examiner Name	Golan	Golam M. SHAMEEM		
Total Number of Pages in This Submission 18			Attorney Docket Numb		USHMR2023 US PCT		
ENCLOSURES (Check all that apply)							
Fee Transmittal Form			l 🗂	Drawing(s)			After Allowance Communication to TC Appeal Communication to Board
Fee Attached				Licensing-related Papers			of Appeals and Interferences
Document(s)		Remark				Appeal Communication to TC Appeal Notice, Brist, Reply Brief) Proprietary Information Status Letter Dither Enclosure(s) (please Identify pelow):	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
AVENTIS PHARMACEUTICALS INC.							
Signature Salvana Communication of the Salvan							
Printed name Barbara E. KURYS							
Date May 20, 2005			Reg. No.			34650	
CERTIFICATE OF TRANSMISSION/MAILING							
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mall in an envelope addressed to: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO, 571-273-0706 ; Total No, of Pages Transmitted; 18							
Ganace Sten							
Typed or printed name		Bonnie Stein	Bonnie Stein			Di	ate May 20, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a banefit by the public which is to five (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the inclindance commences, any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner:

SHAMEEM, Golam M.

David M. FINK, et al.

Art Unit:

1626

Application No.:

10/088,250

Filed:

December 23, 2002

TELEFAX CERTIFICATE

Title:

THIENOSOXAZOLYL-AND

THIENYLPYRRAZOLYL PHENOXY

SUBSTITUTED PROPYL

DERIVATIVES USEFULE AS D4

ANTAGONISTS

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

May 20, 2005

Bornie Stein X

AMENDMENT AND REPLY TO RESTRICTION REQUIREMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is responsive to the telephone call received from the Examiner on May 19, 2005, concerning a revised restriction requirement in relation to the captioned patent application.